We found several maternal glycaemic and neonatal adiposity benefits in the metformin group. Along with reduced maternal weight gain and insulin dosage and improved glycaemic control, the lower adiposity and infant size measurements resulted in fewer large infants but a higher proportion of small-for-gestational-age infants. Understanding the implications of these effects on infants will be…

An increased incidence of gestational diabetes and rising numbers of young women with type 2 diabetes continue to focus attention on the management of hyperglycaemia in pregnancy.1 Although the default glucose-lowering medication in pregnancy is insulin, the most common initial glucose-lowering drug for type 2 diabetes is metformin. So, does the use of metformin to assist glycaemic control in…